PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients.

In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis.

In-hospital outcomes were similar to those of younger patients, though the 90 year olds often required a longer hospital stay.

Mortality at 30 days and stroke also resulted equivalent between 90 year olds and younger patients, major bleeding being the only disadvantage for the eldest patients (+90 years 11%, 80-90 years 9.8% and -80 years 6.9%; p=0.04), though this difference disappeared when adjusting by baseline characteristics. Echocardiography end points did not favor patients over 90, since they showed a higher prevalence of paravalvular leak, both at discharge and at one year.

More articles by this author

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with...

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN...

CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery

At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These...

DANAMI 3: Deferred Stenting and Ischemic Postconditioning Have No Benefit in Primary PCI

Both ischemic postconditioning and deferred stenting showed no benefit in randomized studies conducted as part of the DANAMI 3 program. Both the DANAMI 3-DEFER and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...